Insider Trading activities of Hollis Eden Pharmaceuticals Inc /de/ insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Hollis Eden Pharmaceuticals Inc /de/ since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Hollis Eden Pharmaceuticals Inc /de/ since year 2005. Table 2 shows the detailed insider transactions of Hollis Eden Pharmaceuticals Inc /de/ since 2005. The reporting company's ticker symbol is HEPH. The reporting company's CIK number is 899394.
The total value of stock buying since 2005 is $94,830.
The total value of stock sales since 2005 is $265,074.
The total value of stock option exercises since 2005 is $85,162.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Hollis Eden Pharmaceuticals Inc /de/ (HEPH).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2011-10 75,000 $11,250 0 $0 0 $0
2007-03 0 $0 3,000 $15,909 3,000 $6,750
2007-02 0 $0 8,249 $45,346 3,000 $6,750
2007-01 0 $0 3,000 $16,169 3,000 $6,750
2006-12 15,000 $83,580 0 $0 0 $0
2006-08 0 $0 650 $4,712 650 $1,462
2006-03 0 $0 23,200 $145,888 23,200 $52,200
2006-01 0 $0 5,000 $37,050 5,000 $11,250

Table 2. Detailed insider stock purchases, sales, and option exercises of Hollis Eden Pharmaceuticals Inc /de/ insiders (HEPH)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2011-10-28 Frincke James M (CEO) Buy 25,000 .16 4,000
2011-10-27 Frincke James M (CEO) Buy 25,000 .16 4,000
2011-10-18 Frincke James M (CEO) Buy 25,000 .13 3,250
2007-03-05 Weber Robert W (CAO/VP Controller) Sale 3,000 5.30 15,909
2007-03-05 Weber Robert W (CAO/VP Controller) Option Ex 3,000 2.25 6,750
2007-02-14 Reading Christopher (Executive VP, Sci. Development) Sale 937 5.50 5,156
2007-02-14 Burgess Daniel D (COO/CFO) Sale 2,250 5.50 12,375
2007-02-14 Loumeau Eric J (VP, Corporate General Counsel) Sale 937 5.50 5,156
2007-02-13 Frincke James M (Chief Scientific Officer) Sale 1,125 5.71 6,423
2007-02-05 Weber Robert W (CAO/VP Controller) Sale 3,000 5.41 16,236
2007-02-05 Weber Robert W (CAO/VP Controller) Option Ex 3,000 2.25 6,750
2007-01-08 Weber Robert W (CAO/VP Controller) Sale 3,000 5.39 16,169
2007-01-08 Weber Robert W (CAO/VP Controller) Option Ex 3,000 2.25 6,750
2006-12-12 Mcdonnell Brendan (Director) Buy 10,000 5.66 56,600
2006-12-08 Sarni Marc R (Director) Buy 5,000 5.40 26,980
2006-08-21 Weber Robert W (CAO/VP Controller) Sale 650 7.25 4,712
2006-08-21 Weber Robert W (CAO/VP Controller) Option Ex 650 2.25 1,462
2006-03-13 Weber Robert W (CAO/VP Controller) Sale 18,200 6.29 114,459
2006-03-13 Weber Robert W (CAO/VP Controller) Option Ex 18,200 2.25 40,950
2006-03-10 Mcdonnell Brendan (Director) Sale 5,000 6.29 31,429
2006-03-10 Mcdonnell Brendan (Director) Option Ex 5,000 2.25 11,250
2006-01-30 Mcdonnell Brendan (Director) Sale 5,000 7.41 37,050
2006-01-30 Mcdonnell Brendan (Director) Option Ex 5,000 2.25 11,250

Insider trading activities including stock purchases, stock sales, and option exercises of HEPH listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Hollis Eden Pharmaceuticals Inc /de/ (symbol HEPH, CIK number 899394) see the Securities and Exchange Commission (SEC) website.